China Shineway Pharmaceutical Group Limited
2877
Clasificación en acciones
#11104
As an investment holding enterprise, China Shineway Pharmaceutical Group... As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product range includes modern Chinese pharmaceuticals delivered as soft capsules, granular preparations, and injectable forms, alongside specialized Traditional Chinese Medicine (TCM) Formula Granules. These offerings cater to a broad spectrum of therapeutic needs, such as cardiovascular and cerebrovascular health, anti-viral applications, orthopedic conditions, pediatric ailments, gynecological care, and gastrointestinal issues. Furthermore, the company is involved in the trading of agricultural commodities. Founded in 2004, its headquarters are situated in Shijiazhuang, PRC, and it functions as a subsidiary of Forway Investment Limited.
Precio por acción
$0.93796319
Capitalización bursátil
$708.54M
Cambio (1 día)
-1.85%
Cambio (1 año)
-95.13%
País
CN
Comercio China Shineway Pharmaceutical Group Limited (2877)
Categoría
Healthcare
Ingresos de China Shineway Pharmaceutical Group Limited (2877)
Ingresos en Oct 2026 TTM: 0
Según los últimos informes financieros de China Shineway Pharmaceutical Group Limited, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de China Shineway Pharmaceutical Group Limited desde 2026 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
